Guardant data another step forward for tissue-agnostic diagnostics

Guardant Health's NGS-based liquid biopsy test can identify microsatellite instability in cancer patients, offering a less invasive option for screening patients who could benefit from tissue-agnostic immunotherapies. The data were published in a Clinical Cancer Research paper Monday.

Microsatellite instability (MSI)

Read the full 419 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE